SKINCARE STIMULANT HAVING A PLATELET DRY POWDER

Abstract

A skincare stimulant having an effective dose of platelets and pharmaceutically acceptable solvents and/or excipients, where the effective dose refers to the presence of at least 1000 platelets in every milliliter of skincare stimulant. A method for treating a skin condition selected wrinkles, amyloidosis and keratosis pilaris includes spraying or spreading the skincare stimulant having over a body area, where the skincare stimulant is a solution having a concentration of 1000-10000 platelets per milliliter of the solution, wherein a source of the platelets is a platelet dry powder having less than 30% of plasma protein, based on the weight of the platelet dry powder.

Claims

1. A method for treating a skin condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris, comprising: a step for identifying a body area having a condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris; and a step for spraying or spreading a skincare stimulant having platelets over said body area, wherein the skincare stimulant is a solution having a concentration of 1000-10000 platelets per milliliter of the solution; wherein a source of the platelets is a platelet dry powder having less than 30% of plasma protein, based on the weight of the platelet dry powder.

2. The method of claim 1 further comprising a step for cleaning the body area before said skincare stimulant being sprayed or spread over the body area.

3. The method of claim 2, wherein said cleaning step comprises rinsing, disinfecting or a combination thereof.

4. The method of claim 3 further comprising an absorption-enhancing step after said cleaning step, and said absorption-enhancing step is executed before, during, or after the spraying or spreading step.

5. The method of claim 4, wherein said absorption-enhancing step is executed before the spraying or spreading step by utilizing a laser treatment, micro-needle guiding, or physical stimulation.

6. The method of claim 1, wherein the solution uses water or saline as a solvent thereof.

7. The method of claim 1, wherein the platelets are autologous platelets.

8. The method of claim 1, wherein the concentration is 3000 platelets per milliliter of the solution.

9. The method of claim 8, wherein the concentration is 5000 platelets per milligram of the solution.

10. The method of claim 1, wherein said skin condition is wrinkles.

11. The method of claim 1, wherein said skin condition is amyloidosis.

12. The method of claim 1, wherein said skin condition is keratosis pilaris.

13. A method for treating a skin condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris, comprising: a step for identifying a body area having a condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris; a step for preparing a skincare stimulant having platelets comprising mixing water or saline with a platelet dry powder to form a solution having a concentration of 1000-10000 platelets per milliliter of the solution, wherein the platelet dry powder contains less than 30% of plasma protein, based on the weight of the platelet dry powder; and a step for spraying or spreading the skincare stimulant over said body area.

14. A method for treating a skin condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris, consisting essentially of: a step for identifying a body area having a condition selected from the group consisting of wrinkles, amyloidosis and keratosis pilaris; and a step for spraying or spreading a skincare stimulant having platelets over said body area, wherein the skincare stimulant is a solution having a concentration of 1000-10000 platelets per milliliter of the solution; wherein a source of the platelets is a platelet dry powder having less than 30% of plasma protein, based on the weight of the platelet dry powder.

Description

BRIEF DESCRIPTION OF DRAWINGS

[0030] FIGS. 1a and 1b are photographs showing the patient in Embodiment 1 before and after the treatments.

[0031] FIGS. 2a and 2b are photographs showing the patient in Embodiment 2 before and after the treatments.

[0032] FIGS. 3a and 3b are photographs showing the patient in Embodiment 3 before and after the treatments.

[0033] FIGS. 4a and 4b are photographs showing the patient in Embodiment 4 before and after the treatments.

[0034] FIGS. 5a and 5b are photographs showing the patient in Embodiment 5 before and after the treatments.

[0035] FIGS. 6a and 6b are photographs showing the patient in Embodiment 6 before and after the treatments.

[0036] FIGS. 7a and 7b are photographs showing the patient in Embodiment 7 before and after the treatments.

[0037] FIGS. 8a and 8b are photographs showing the patient in Embodiment 8 before and after the treatments.

[0038] FIGS. 9a and 9b are photographs showing the patient in Embodiment 9 before and after the treatments.

[0039] FIGS. 10a and 10b are photographs showing the patient in Embodiment 10 before and after the treatments.

[0040] FIGS. 11a and 11b are photographs showing the patient in Embodiment 11 before and after the treatments.

[0041] FIGS. 12a and 12b are photographs showing the patient in Embodiment 12 before and after the treatments.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0042] The preferred embodiments are described hereafter in order to further elucidate the techniques of the invention:

Testing Example:

[0043] The method disclosed in the announced Taiwan patent TW-I270375 was used to prepare a platelet dry powder. 1.0 g of platelet dry powder was obtained and added to saline to make up 5.0 mL of solution, then the PDGF titer of the solution was analyzed by using a spectrophotometer (U.S. Bio-Tek Instruments, Inc., Model -Quant) immediately after preparation (0 hour), after 1 week (168 hours), after 2 weeks (336 hours), after 3 weeks (504 hours), and after 4 weeks (672 hours).

[0044] Results from the analyses are shown in Table 1.

TABLE-US-00001 TABLE 1 Changes of PDGF titer in the solution prepared from the platelet dry powder. Weeks 0 1 2 3 4 5 6 PDGF 2930 2795 3012 2854 2822 2776 2785 (pg/mL)

[0045] The experimental figures show: The PDGF titer of the platelet dry powder is very stable.

Embodiment 1

[0046] The method disclosed in the announced patent TW-I270375 was used to prepare an autologous platelet dry powder from autologous blood in advance. The platelet dry powder was added to water obtained by reverse osmosis (RO) to prepare a solution having 5000 platelets/mL therein, then the solution was held in a spray bottle. The number of platelets in the solution was measured by using a Hematology Analyzer (Manufacturer: Sysmex, Model: KX-21).

[0047] A patient was allowed to undergo a treatment for skincare stimulation once a week, which involved firstly disinfecting a body area awaiting the skincare stimulation, and then carrying out laser treatment on the disinfected body area, followed by evenly spraying the skincare stimulant (solution) on the disinfected body area. In addition, between every two treatments, the body area awaiting the skincare stimulation was evenly sprayed with the skincare stimulant after washing face everyday.

[0048] The FIGS. 1a and 1b show the conditions of the body area awaiting the skincare stimulation before the treatments and 4 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation showed significantly increased skin elasticity and firmness; the pores became smaller and the skin became whiter and clearer.

Embodiment 2

[0049] Similar to Embodiment 1, the FIGS. 2a and 2b show the conditions of the body area awaiting the skincare stimulation before the treatments and 7 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results indicated: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, showed significantly increased skin elasticity and firmness; the pores became smaller and the skin became whiter and clearer.

Embodiment 3

[0050] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 10000. The FIGS. 3a and 3b show the conditions of the body area awaiting the skincare stimulation before the treatments and 2 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller while the skin became whiter and clearer.

Embodiment 4

[0051] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 5000. The FIGS. 4a and 4b show the conditions of the body area awaiting the skincare stimulation before the treatments and 4 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller and the skin became whiter and clearer.

Embodiment 5

[0052] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 5000. The FIGS. 5a and 5b show the conditions of the body area awaiting the skincare stimulation before the treatments and 4 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent; scars thereon became lighter (please refer to the picture between FIGS. 5a and 5b); showed significantly increased skin elasticity and firmness; the pores became smaller and the skin became whiter and clearer.

Embodiment 6

[0053] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 5000. The FIGS. 6a and 6b show the conditions of the body area awaiting the skincare stimulation before the treatments and 7 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller and the skin became whiter and clearer.

Embodiment 7

[0054] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 5000. The FIGS. 7a and 7b show the conditions of the body area awaiting the skincare stimulation before the treatments and 7 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller and the skin became whiter and clearer.

Embodiment 8

[0055] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 3000. The FIGS. 8a and 8b show the conditions of the body area awaiting the skincare stimulation before the treatments and 24 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller while the skin became whiter and clearer.

Embodiment 9

[0056] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 3000. The FIGS. 9a and 9b show the conditions of the body area awaiting the skincare stimulation before the treatments and 21 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller while the skin became whiter and clearer.

Embodiment 10

[0057] Similar to Embodiment 1, but the platelet dry powder was a heterologous platelet dry powder prepared from bovine blood, and the concentration of the skincare stimulant (platelet number/mL of solution) was 5000. The FIGS. 10a and 10b show the conditions of the body area awaiting the skincare stimulation before the treatments and 3 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness, and the pores became smaller and the skin became whiter and clearer.

Embodiment 11

[0058] Similar to Embodiment 1, but the platelet dry powder was a heterologous platelet dry powder prepared from bovine blood, and the concentration of the skincare stimulant (platelet number/mL of solution) was 3000. The FIGS. 11a and 11b show the conditions of the body area awaiting the skincare stimulation before the treatments and 8 weeks after the treatments, wherein the photographs on the right are the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness; the pores became smaller and the skin became whiter and clearer.

Embodiment 12

[0059] Similar to Embodiment 1, but the platelet dry powder was a homologous platelet dry powder prepared from the blood in a blood bank, and the concentration of the skincare stimulant (platelet number/mL of solution) was 1000. The FIGS. 12a and 12b show the conditions of the body area awaiting the skincare stimulation before the treatments and 19 weeks after the treatments, wherein the photographs on the right re the partially magnified pictures of the photographs on the left. The results showed: the body area awaiting the skincare stimulation had wrinkles that either vanished or became less apparent, and spots thereon became lighter in color; showed significantly increased skin elasticity and firmness; the pores became smaller, and the skin became whiter and clearer.

[0060] The results from the embodiments indicate that: with respect to the effects of the treatments, the heterologous PLT appeared to outperform the homologous PLT and the autologous PLT. However, considering the patients' possible concerns, it is preferable to use homologous PLT or autologous PLT, and is more preferable to use autologous PLT.